Health Care · Pharmaceutical Preparations

NUVB Nuvation Bio Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 181106374 filings
Russell 2000

NUVB at a glance

Nuvation Bio Inc. (NUVB, SEC CIK 1811063) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as August 21, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Nuvation Bio Inc. (NUVB) reported revenue of $62.9 million (up 699.0% from FY2024) and a net loss of $204.6 million. Diluted EPS was -$0.60.
  • As of September 30, 2026, 32 institutional investment managers tracked by SignalX reported holding Nuvation Bio Inc. (NUVB) shares worth $448.6 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Hattersley Gary on August 19, 2026 of 100,000 shares at $7.09 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$62.9M
+699.0% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
32 funds
$448.6M · +1 vs prior quarter
Latest 8-K
Nov 4, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Global oncology focused on developing novel small molecule therapies for difficult-to-treat cancers, leveraging medicinal chemistry and clinical data
  • New emphasis: U.S. commercial launch of IBTROZI (taletrectinib) for ROS1+ NSCLC approved June 2025, plus new Eisai partnership for European and other territories in 2026
  • Strategic shift: Expansion into global commercialization via partnerships in China, Japan, Europe, and additional territories, extending reach beyond prior regional focus
  • Quantitative highlight: 71 U.S. commercial field team members for IBTROZI launch, with nearly 300 patients enrolled in pivotal Phase 2 global clinical trial program
  • Noteworthy: Median duration of response for IBTROZI matured to 50 months by August 2025, supporting its potential as new standard of care in ROS1+ NSCLC

Risk Factors

  • Regulatory risk: FDA approval and post-approval obligations for IBTROZI (taletrectinib) granted June 11, 2025 for ROS1+ NSCLC treatment
  • Geopolitical risk: Commercial partnerships in Japan (NK) and China (Innovent) expose revenue to MHLW and NMPA regulatory environments
  • Operational risk: High R&D expenses increased by $16M in 2025 driven by clinical trial costs and headcount growth, with continued need for funding
  • Competitive risk: Phase 3 TRUST-III study compares taletrectinib to crizotinib in China, a key competitor in ROS1+ NSCLC market
  • Financial risk: $250M non-dilutive financing includes $150M synthetic royalty financing with tiered royalties up to 2.0x investment, plus $100M senior secured loan at SOFR+6% interest

Management Discussion & Analysis

  • Revenue and profitability data not disclosed in MD&A section
  • No cash flow, buybacks, dividends, or capex information given
  • Forward-looking statements caution on risks causing actual results to differ materially

AI summary of the NUVB 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Newly added debt risk: $287.5 million of 0.75% Convertible Senior Notes due 2032 issued in July 2026
  • Most material commercialization risk: IBTROZI became the sole FDA-approved product after June 2025 approval, concentrating near-term revenue dependence
  • Regulatory risk: U.S. approval requires pediatric, hepatic impairment, drug interaction and companion-diagnostic post-marketing commitments
  • Operational risk: Single-source taletrectinib API supply while developing a second source
  • Liquidity risk: $663.4 million cash and investments expected to fund operations for at least 12 months, subject to operating-plan assumptions

Management Discussion & Analysis

  • Q3 revenue $44.951M, up $31.831M YoY from $13.120M
  • Product revenue $27.457M, up from $7.723M; collaboration revenue $17.494M, up from $5.397M
  • Q3 operating margin -93.9% vs -429.8% YoY, based on total costs and expenses
  • Cash $663.4M at September 30, 2026; operating cash outflow $76.461M for nine months
  • $279.1M net convertible-note proceeds, $58.7M debt repayment, $17.1M capped-call cost; liquidity expected through at least 12 months

AI summary of the NUVB 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release covers Nuvation Bio’s quarter ended September 30, 2026
  • Investors should review Exhibit 99.1 for financial results and operating updates

Item EX-99.1: Item EX-99.1

  • Q3 revenue $45.0M, up from $13.1M, driven by IBTROZI product revenue $27.5M and collaboration revenue $17.5M
  • IBTROZI revenue grew 18% sequentially, with approximately 160 new patient starts despite a 15% market decline
Filed Aug 6, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 financial results released for quarter ended June 30, 2026
  • Full operating metrics and financial details contained in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q2 revenue $31.7M, including $23.2M IBTROZI product sales, signaling accelerating commercial adoption
  • IBTROZI sales grew 25% QoQ, with approximately 85% of 160 new starts TKI-naïve
Filed Jul 6, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • Additional capped calls executed July 1, 2026, tied to the Greenshoe Exercise
  • Designed to reduce potential Class A common-stock dilution upon convertible-note conversion

Item EX-99.1: Item EX-99.1

  • Greenshoe fully exercised, increasing convertible notes offering to $287.5 million
  • Notes carry 0.75% interest and mature in 2032, adding low-cost long-term financing

Item 2.03: Creation of a Direct Financial Obligation

  • $287.5M convertible notes issued, including $37.5M greenshoe exercise, expanding long-term financing
  • 0.75% annual interest, $1.00B? 2032 maturity?

Item 8.01: Other Events

  • July 6, 2026 press release announces additional convertible Notes issued through the Greenshoe Exercise
  • Additional capped call confirmations entered, potentially reducing future equity dilution from note conversions

AI summaries of NUVB 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for NUVB

Don't miss the next NUVB filing

  • Alerts as it files. A push when NUVB files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut NUVB, by share count.
  • Ask anything. An AI agent that reads every NUVB filing and answers with sources.

NUVB alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Hattersley GaryMAug 19, 2026-
Hattersley GaryMAug 19, 2026$1.87
Hattersley GarySellAug 19, 2026$7.09
Sauvage PhilippeMJul 15, 2026$1.97
Sauvage PhilippeMJul 15, 2026-
Sauvage PhilippeMJul 15, 2026$2.17
Sauvage PhilippeMJul 15, 2026-
Markel StacyMJun 23, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$0$7.9M$62.9M
Gross Profit$0$795K-
Operating Income--$592.6M-$213.1M
Net Income--$567.9M-$204.6M
Gross Margin-10.1%-
Op. Margin--7527.3%-338.7%
Net Margin--7213.8%-325.3%
Balance Sheet
Total Assets-$540.6M$594.8M
Equity$605.1M$463.8M$305.7M
ROE--122.5%-66.9%
Per Share
EPS$-0.35$-2.11$-0.60
Cash Flow
Operating CF-$68.0M-$130.4M-$173.4M

Source: XBRL data in Nuvation Bio Inc. (NUVB)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate NUVB share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
NUVB shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202632$448.6M
Q2 202631$707.2M
Q1 202631$516.4M
Q4 202528$1.06B
Q3 202527$449.0M
Q2 202527$238.8M
Q1 202524$153.1M
Q4 202419$206.1M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 219 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

NUVB filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 4, 2026Analysis
8-KNov 4, 2026Analysis-
4Aug 21, 2026--
10-QAug 6, 2026Analysis
8-KAug 6, 2026Analysis-
4Jul 17, 2026--
8-KJul 6, 2026Analysis-
8-KJun 30, 2026Analysis-
4Jun 24, 2026--
4Jun 24, 2026--
4Jun 24, 2026--
4Jun 11, 2026--
8-KMay 27, 2026Analysis
4May 26, 2026-
4May 26, 2026-
4May 26, 2026-
4May 26, 2026-
4May 26, 2026-
4May 26, 2026-
4May 26, 2026-
8-KMay 4, 2026Analysis-
10-QMay 4, 2026Analysis
4Apr 21, 2026--
4Apr 21, 2026--
4Apr 8, 2026--

Related Health Care companies

All Health Care →

NUVB SEC filings: frequently asked questions

Which institutions hold NUVB stock?

As of September 30, 2026, the largest Nuvation Bio Inc. (NUVB) holders among the 13F filers tracked by SignalX were BlackRock ($162.0 million), Vanguard Capital Management LLC ($68.1 million), State Street Corp ($42.5 million), Goldman Sachs Group ($25.3 million), Two Sigma Investments ($18.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was NUVB's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Nuvation Bio Inc. (NUVB) reported revenue of $62.9 million (up 699.0% from FY2024) and a net loss of $204.6 million. Diluted EPS was -$0.60. The figures come from the XBRL data in the 10-K.

What are the main risks in NUVB's latest 10-K?

In the 10-K filed March 2, 2026, Nuvation Bio Inc. (NUVB) flagged: Regulatory risk: FDA approval and post-approval obligations for IBTROZI (taletrectinib) granted June 11, 2025 for ROS1+ NSCLC treatment. Geopolitical risk: Commercial partnerships in Japan (NK) and China (Innovent) expose revenue to MHLW and NMPA regulatory environments. (AI summary of the Risk Factors section.)

What did NUVB report in its latest 8-K?

Nuvation Bio Inc. (NUVB) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release covers Nuvation Bio’s quarter ended September 30, 2026.

What are the latest NUVB SEC filings?

Nuvation Bio Inc. (NUVB) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on August 21, 2026.

What is NUVB's SEC CIK number?

Nuvation Bio Inc. (NUVB)'s SEC Central Index Key (CIK) is 1811063. EDGAR lists every NUVB filing under that number.

Ask anything about NUVB

The research agent reads NUVB's filings, financials, insider trades and 13F holders, then answers with sources.